Actualizaciones regulatorias
Novedades regulatorias de FDA, EMA, TGA y organismos globales
#ramipril ×
Actualizaciones regulatorias
8 sept 2026•1 min de lectura
FDA Approves Labeling for Teva’s Discontinued Ramipril Capsules (ANDA 077470)
Teva Pharmaceuticals’ oral ramipril capsule products (1.25‑10 mg) were listed as discontinued, with multiple FDA labeling supplements approved between 2008 and 2014.
Actualizaciones regulatorias
31 ago 2026•1 min de lectura
FDA Approves Ranbaxy Ramipril Capsules (ANDA078849)
FDA approves ANDA078849 submitted by Ranbaxy Labs Ltd for oral ramipril 5 mg and 10 mg capsules, both listed as discontinued.
Actualizaciones regulatorias
23 ago 2026•1 min de lectura
Crescent Pharma Recalls Ramipril 10mg Capsules Batch
Crescent Pharma Limited is recalling a batch of Ramipril 10mg capsules as a precaution due to a possible manufacturing error.
Actualizaciones regulatorias
23 ago 2026•1 min de lectura
Crescent Pharma Initiates Precautionary Recall of Ramipril 2.5 mg Capsules
Crescent Pharma Limited is recalling a batch of 2.5 mg Ramipril capsules due to a possible packaging error.